A Merck investment subsidiary was among the backers for the $9.3m round, which follows a $300,000 equity investment in 2009.

MedCPU, a US-based developer of real-time healthcare decision support systems, has secured $9.3m in series B financing from investors including pharmaceutical company Merck.

Founded in 2009, MedCPU’s Advisor technology analyses information from Electronic Medical Records, matching it to best-practice data to devise real-time prompts advising treatments for each patient.

Merck Global Health Innovation Fund invested alongside Easton Capital Investment Group and New Richmond Ventures. MedCPU previously raised $1.3m in convertible debt financing 2011 and $300,000 in equity in 2009, according to SEC filings.

“We’re excited to add MedCPU’s leading technology and team to our growing portfolio and believe that MedCPU is poised to shift the value proposition of decision support,” said Joel Krikston, managing director of the Merck Global Health Innovation Fund.